{
    "clinical_study": {
        "@rank": "43693", 
        "arm_group": {
            "arm_group_label": "NAC Intervention", 
            "arm_group_type": "Experimental", 
            "description": "This is a dose-finding study using a traditional 3+3 dose escalation scheme.  Up to 18 subjects (3 dose levels as per below) will be enrolled to determine the maximum tolerated dose (MTD).  The MTD is defined as per traditional 3+3 criteria of less than or equal to one dose-limiting toxicity at the dose level.  Once the MTD is determined, subjects will be equally distributed at the \"safe\" dose levels (less than or equal to the MTD) to determine the optimum dose to achieve NAC levels in the blood necessary for hearing protection.  The selected dose will then be tested further in an expansion cohort of an additional 6 subjects."
        }, 
        "brief_summary": {
            "textblock": "Cisplatin is a key chemotherapy agent for the treatment of multiple childhood cancers but\n      causes permanent hearing loss. This study investigates the drug N-acetylcysteine (NAC) to\n      determine the dose necessary to protect hearing and also how well tolerated NAC is when\n      combined with chemotherapy."
        }, 
        "brief_title": "NAC to Prevent Cisplatin-induced Hearing Loss", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Neuroectodermal Tumors, Primitive", 
            "Liver Neoplasms", 
            "Neoplasms, Germ Cell and Embryonal", 
            "Osteosarcoma", 
            "Other Childhood Cancers Using Cisplatin-based Regimens"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Hearing Loss", 
                "Deafness", 
                "Liver Neoplasms", 
                "Neoplasms, Germ Cell and Embryonal", 
                "Osteosarcoma", 
                "Neuroectodermal Tumors", 
                "Neuroectodermal Tumors, Primitive"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study is a dose-finding study of N-acetylcysteine (NAC) to protect hearing in children\n      receiving cisplatin for the treatment of their cancer.  NAC also has potential to protect\n      the kidneys from cisplatin toxicity.\n\n      The study uses a 3+3 dose-escalation scheme to determine the dose of NAC necessary to\n      achieve serum levels consistent with hearing protection in pre-clinical animal models. Three\n      dose levels are predefined.  Once the maximum tolerated dose is determined, an expansion\n      cohort will then be enrolled to further evaluate tolerability as well as intra-patient and\n      inter-patient variability in achieved serum levels."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Are between 0 and 21 years of age (inclusive) at time of diagnosis of underlying\n             malignancy\n\n          -  Have a new diagnosis of a localized malignancy with a planned treatment course to\n             include at least two cycles of cisplatin\n\n          -  Diagnosis to be assigned by oncology attending of record (may be reported via\n             designee), histological diagnosis does not need to be confirmed separately\n\n          -  Most common but not exclusive diagnoses consist of high-risk neuroblastoma,\n             hepatoblastoma, germ cell tumor, medulloblastoma, osteosarcoma\n\n          -  Total cumulative dose of planned cisplatin must be >200 mg/m2 (or 6.67 mg/kg\n             equivalent for infants requiring weight-based dosing.  Conversion factor used is\n             30:1).\n\n          -  Planned cisplatin dose to be infused over \u22646 hours\n\n          -  Are anticipated to be able to comply with end-of-therapy audiology assessment (note\n             that hearing assessments are performed per routine clinical care in children\n             receiving cisplatin and consist of an audiogram or auditory brainstem response, and\n             distortion-product otoacoustic emissions)\n\n          -  Patients with any hearing status are eligible for study (as long as they can comply\n             with the study primary aims of assessing toxicity and dose-response)\n\n        Exclusion Criteria:\n\n          -  Inadequate cardiac function as defined by (A) echocardiogram with left ventricular\n             shortening fraction (LVSF) < 28% or ejection fraction (EF) < 55% and/or qualitatively\n             abnormal systolic function, (B) presence of serious arrhythmia on electrocardiogram,\n             or (C) corrected QT interval >480.\n\n          -  previous history of congestive heart failure or congenital arrhythmia (e.g.\n             Wolf-Parkinson-White)\n\n          -  Hepatic, biliary, or bone marrow function inadequate for chemotherapy as per\n             patient's treatment regimen.  There are no additional protocol-specific restrictions\n             for these markers.\n\n          -  Moderate or Severe Persistent Asthma as defined by the latest recommendations from\n             the National Heart Lung and Blood Institute definition includes daily asthma\n             exacerbation with need for rescue medication) or an overnight hospitalization for\n             asthma exacerbation within the previous 28 days\n\n          -  Disseminated disease (e.g. lepto-meningeal spread, tumor metastases)\n\n          -  Karnofsky or Lansky score <50%\n\n          -  Pregnancy or breast-feeding mothers\n\n          -  Documented hypersensitivity or allergy to previous NAC infusion"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "21 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02094625", 
            "org_study_id": "NACCDDP1"
        }, 
        "intervention": {
            "arm_group_label": "NAC Intervention", 
            "description": "NAC will be administered intravenously over ~30 minutes starting 4 hours following completion of cisplatin for the first 3 cycles of chemotherapy. Patients will have the option to continue with NAC for any remaining cycles.\nThree dose levels have been pre-determined:\nDose Level 1: 225 mg/kg Dose Level 2: 300 mg/kg Dose Level 3: 450 mg/kg", 
            "intervention_name": "N-Acetylcysteine", 
            "intervention_type": "Drug", 
            "other_name": [
                "N-acteylcysteine", 
                "acteylcysteine injectable", 
                "Acetadote"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Acetylcysteine", 
                "N-monoacetylcystine", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Cisplatin", 
            "N-acetylcysteine", 
            "Hearing Loss", 
            "Otoprotection"
        ], 
        "lastchanged_date": "March 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Long Beach", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90806"
                    }, 
                    "name": "Miller Children's Hospital Long Beach"
                }, 
                "investigator": [
                    {
                        "last_name": "Etan Orgel, MD MS", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Amanda Termuhlen, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90027"
                    }, 
                    "name": "Childrens Hospital Los Angeles"
                }, 
                "investigator": [
                    {
                        "last_name": "Etan Orgel, MD MS", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "David R Freyer, DO MS", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Dose-Finding Study of N-Acetylcysteine (NAC) to Prevent Cisplatin-induced Hearing Loss in Children With Cancer", 
        "overall_contact": {
            "email": "eorgel@chla.usc.edu", 
            "last_name": "Etan Orgel, MD MS", 
            "phone": "562-933-8600"
        }, 
        "overall_contact_backup": {
            "email": "dfreyer@chla.usc.edu", 
            "last_name": "David Freyer, DO MS", 
            "phone": "323-361-2121"
        }, 
        "overall_official": {
            "affiliation": "Children's Hospital Los Angeles", 
            "last_name": "Etan Orgel, MD MS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Following the first dose of cisplatin, NAC will be administered as described below.  A NAC level will then be measured immediately following this first dose of NAC to determine if the blood (serum) level reaches the threshold necessary for hearing protection.", 
            "measure": "Target Serum Level NAC", 
            "safety_issue": "No", 
            "time_frame": "On average up to 8 weeks from diagnosis"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02094625"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Children's Hospital Los Angeles", 
            "investigator_full_name": "Etan Orgel", 
            "investigator_title": "Assistant Professor of Clinical Pediatrics", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Subjects will be monitored during and after each NAC infusion to determine how well they tolerate the drug. Infusion rate related and spontaneously resolving \"anaphylactoid\" reactions are the most common reported toxicity and will be closely monitored. Most subjects will receive 3 cycles of cisplatin and NAC, typically within the first 15 weeks of starting chemotherapy. Subjects who opt to continue to receive NAC following the first 3 cycles will continue to be monitored.", 
                "measure": "Adverse events during infusion of NAC", 
                "safety_issue": "Yes", 
                "time_frame": "Up to approximately 40 weeks from start of chemotherapy (regimen dependent)"
            }, 
            {
                "description": "A NAC serum level will be measured surrounding the first dose of NAC at 4 times:\npre-cisplatin (baseline)\nfollowing cisplatin/before NAC\nimmediately following NAC (primary aim)\ndelayed four hours following NAC", 
                "measure": "NAC Level", 
                "safety_issue": "No", 
                "time_frame": "-6,0, 0.5, and 4 hours from start of first NAC dose (intervention)"
            }, 
            {
                "description": "Routinely performed hearing assessments will be analyzed at the end of therapy as compared to a historical cohort and also to patient's baseline (if available) to evaluate for any trend toward a protective effect from NAC.", 
                "measure": "Hearing assessment", 
                "safety_issue": "No", 
                "time_frame": "Up to approximately 40 weeks from start of chemotherapy"
            }, 
            {
                "description": "Information regarding renal toxicity due to cisplatin will be collected at end of therapy and compared to historical rates to evaluate a potential protective effect by NAC", 
                "measure": "Renal Toxicity", 
                "safety_issue": "No", 
                "time_frame": "Up to approximately 40 weeks from start of chemotherapy"
            }, 
            {
                "description": "Early indicators of tumor response to cisplatin-based chemotherapy (e.g. percent necrosis in resected tumors, early remission rates, etc) will be informally evaluated in comparison to historical data for any evidence NAC decreases efficacy of the chemotherapy", 
                "measure": "Response of tumor to treatment", 
                "safety_issue": "No", 
                "time_frame": "On average up to 15 weeks from start of chemotherapy (regimen dependent)"
            }, 
            {
                "description": "Saliva/cheek swabs will be collected one-time for genotype analysis to examine the influence of glutathione polymorphisms on cisplatin-induced hearing loss and NAC hearing protection", 
                "measure": "Effect of Genotype on Hearing Loss and Hearing Protection", 
                "safety_issue": "No", 
                "time_frame": "On average up to 15 weeks from start of chemotherapy"
            }, 
            {
                "description": "Glutathione serum levels will be measured at times corresponding to NAC levels surrounding the first dose of NAC at 4 times:\npre-cisplatin (baseline)\nfollowing cisplatin/before NAC\nimmediately following NAC (primary aim)\ndelayed four hours following NAC", 
                "measure": "Glutathione serum level", 
                "safety_issue": "No", 
                "time_frame": "-6,0, 0.5, and 4 hours from start of first NAC dose (intervention)"
            }
        ], 
        "source": "Children's Hospital Los Angeles", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Children's Hospital Los Angeles", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}